Latest News
Global brain and vision research nonprofit BrightFocus Foundation and the Helen Keller Foundation for Research and Education have named ophthalmologist José Cunha-Vaz, MD, PhD, the recipient of the 2024 Helen Keller Prize for Vision Research in recognition of his immense contributions to the field.
On May 6, BrightFocus Foundation recognized five vision scientists for their research focused on preventing, treating, and curing macular degeneration and glaucoma during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO).
Global nonprofit BrightFocus Foundation announces $10 million in new Alzheimer’s disease, macular degeneration, and glaucoma research grant funding—age-related diseases with no cure that affect more than 335 million people worldwide.
In This Issue:
- President’s Corner
- Exercise-Induced Hormone Could Treat Alzheimer’s Disease
- Researcher Spotlight: Ariel Gilad, PhD
- Tips for Managing Caregiver Stress
- Zoom In on Dementia & Alzheimer’s
- Help Fight Alzheimer’s Through a Will or Bequest
BrightFocus Foundation, a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma, has welcomed Jon Walsh as its new Senior Vice President, Finance and Administration.
A promising new treatment for individuals suffering from stroke, concussion, and traumatic brain injury, known risk factors for dementia, has received approval from the U.S. Food & Drug Administration to move into Phase 2 clinical trials. Learn more.
Learn how our funded scientists are advancing new ways of diagnosing Alzheimer’s disease earlier and more accurately.
Alzheimer’s Disease Research, a BrightFocus Foundation program, joined over 4,500 scientists, physicians, and industry leaders from 70 countries at the annual International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Lisbon, Portugal. Read our key takeaways.
The company behind the first-of-its-kind blood-based screening test for Alzheimer’s disease—rooted in pivotal early BrightFocus support—has received a $15 million investment that will broaden access to the blood test for patients and doctors.
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
